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Background: Polypharmacy of respiratory medications is commonly observed in patients 
with chronic obstructive pulmonary disease (COPD). The aims of this study were to investigate 
determinants of polypharmacy and to study the consistency of actual respiratory drug use with 
current Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines in pulmonary 
rehabilitation candidates with COPD.
Methods: Data were extracted from the records of all patients with a diagnosis of COPD 
referred for pulmonary rehabilitation to CIRO+ between 2005 and 2009. Use of respiratory 
medications, self-reported COPD exacerbations, lung function, blood gases, exercise capacity, 
Medical Research Council (MRC) dyspnea grade, and St George’s Respiratory Questionnaire 
(SGRQ) were recorded as part of assessment of health status.
Results: In total, 1859 COPD patients of mean age (± standard deviation) 64.3 ± 9.7 years and 
with a forced expiratory volume in one second (FEV1) of 44.7% ± 18.2% were included. On 
average, patients used 3.5 ± 1.5 respiratory medications; this number increased with increasing 
GOLD stage, MRC score, and SGRQ scores. FEV1 (% predicted), SGRQ, and number of recent 
exacerbations were independent determinants of polypharmacy. Use of long-acting bronchodi-
lators and inhaled corticosteroids was substantial and comparable in all GOLD stages. Use of 
corticosteroids was not restricted to patients with frequent exacerbations.
Conclusion: Polypharmacy of respiratory medications is common in COPD patients with 
persistent symptoms. In addition to severity of disease, health status is an independent predic-
tor of polypharmacy. Actual drug use in COPD patients referred for pulmonary rehabilitation 
is partially inconsistent with current GOLD guidelines.
Keywords: chronic obstructive pulmonary disease, management, pharmacotherapy, 
polypharmacy, pulmonary rehabilitation, respiratory drug use
Introduction
Chronic obstructive pulmonary disease (COPD) is a major cause of morbidity and 
mortality worldwide and results in substantial social and economic burden, includ-
ing both direct and indirect costs.1 It is projected that the burden of this disease will 
increase in the next decade and that COPD will become the third leading cause of 
death by 2020.2
Although the chronic airflow limitation characteristic of the disease cannot be 
cured, both pharmacologic and nonpharmacologic treatment is available for patients 
with COPD. Effective pharmacologic management of the disease results in relief of 
symptoms,3,4 improvement in lung function,3,5,6 health status,5,6 exercise tolerance,7,8 
and reduction in frequency5,6 and severity of exacerbations.9 Until now, modification 
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of disease progression4,5 and mortality6,10 by pharmacotherapy 
has not been convincingly demonstrated, although several 
recent trials suggest a beneficial effect of pharmacologic 
treatment on the rate of decline in lung function.11–13
In order to provide a benchmark for evidence-based 
pharmacologic therapy and facilitate the development 
of cost-effective care, the Global Initiative for Chronic 
Obstructive Lung Disease (GOLD) consensus statement14 
provides recommendations for pharmacotherapy in COPD. 
In clinically stable patients, the introduction of respiratory 
medications according to these guidelines follows a step-up 
principle based on the level of disease severity assessed by 
postbronchodilator forced expiratory volume in the first 
second (FEV1), the presence of clinical symptoms, and the 
occurrence of acute exacerbations. Recommended initial 
pharmacotherapy consists of short-acting bronchodilators, 
followed by the introduction of long-acting bronchodila-
tors in moderately severe patients with persisting dyspnea 
and the addition of inhaled corticosteroids in patients with 
severe or very severe disease and recurring exacerbations. 
Xanthine derivates may provide additional reduction of 
symptoms cumulative to long-acting bronchodilators. 
According to current evidence, chronic use of systemic cor-
ticosteroids must be avoided.14 Finally, antioxidant agents 
have no additional benefit in the pharmacologic treatment 
of stable COPD.14
To date, no studies have assessed whether the routine 
practice of respiratory physicians is consistent with these 
international guidelines for pharmacotherapy in COPD. In 
clinical practice, polypharmacy with respiratory drugs is 
commonly observed. This substantially contributes to direct 
medical costs in COPD.1 In addition, overuse of respiratory 
medications is an important risk factor for adverse effects.15 
Furthermore, polypharmacy and prescription of multiple 
daily doses contribute to poor patient adherence in COPD, 
which is a significant concern.16 Although higher age, female 
gender, and the presence of multiple comorbidities are some 
of the factors correlated with polypharmacy in the elderly,17 
determinants of polypharmacy with respiratory medications 
in COPD have not yet been investigated.
The primary aim of the present study was to explore fac-
tors related to polypharmacy with respiratory drugs, including 
age, gender, health status, and the occurrence of exacerba-
tions in COPD patients with persistent symptoms referred for 
clinical assessment and pulmonary rehabilitation. Secondly, 
the consistency of prescriptions and actual use of respiratory 
drugs with the current GOLD guidelines for pharmacotherapy 
was investigated in a tertiary care setting.
Methods
Subjects
Data were extracted from the records of all patients admitted 
to CIRO+, Center of Expertise for Chronic Organ Failure 
in Horn, The Netherlands, for clinical evaluation and 
pulmonary rehabilitation between January 1, 2005 and 
December 31, 2009. Referral to the center is reserved to respi-
ratory physicians. Only data from patients with a primary 
diagnosis of COPD confirmed by the referring respiratory 
physician were included in this study. Data from patients with 
alternative or additional respiratory conditions, including 
asthma or lung cancer, were excluded. In addition, spirometric 
data from patients had to fulfill the criteria of chronic airflow 
limitation, defined as postbronchodilator forced expiratory 
volume in one second (FEV1)/forced vital capacity ,0.7.14 
These retrospective analyses are Institutional Review Board 
exempt due to the use of deidentified, pre-existing data. Some 
of the patients were part of a previous paper on problematic 
activities in daily life.18
Assessment of respiratory drug  
therapy and exacerbations
During medical consultation at CIRO+, all respiratory drugs 
prescribed by secondary care respiratory physicians were 
routinely recorded, and the actual use of these drugs was 
verified with the patients. Respiratory medications were 
stratified into six classes, ie, short-acting bronchodilators 
(short-acting β2-agonists, short-acting anticholinergics, short-
acting combined bronchodilators), long-acting bronchodila-
tors (long-acting β2-agonists alone or in combination with 
inhaled corticosteroids, and long-acting anticholinergics), 
inhaled corticosteroids (alone or in combination with long-
acting β2-agonists), systemic corticosteroids, theophylline, 
and N-acetylcysteine. The number of patient-reported 
COPD exacerbations in the 12 months prior to assessment 
was consistently annotated during medical history. If pos-
sible, exacerbations were verified in the written medical 
correspondence from the referring respiratory physician 
on application for pulmonary rehabilitation. Patients with 
three or more exacerbations in the last year were considered 
frequent exacerbators.19
Clinical assessment
In order to evaluate the integrated health status of referred 
patients, a comprehensive assessment was routinely per-
formed at the CIRO+.20 Postbronchodilator FEV1 and forced 
vital capacity were calculated from the flow-volume curve 
using spirometry. Carbon monoxide transfer factor of the 
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lung (DLCO) was determined using the single breath method. 
Lung function parameters were expressed as a percentage of 
reference values.21 Arterial oxygen tension and arterial carbon 
dioxide tension were analyzed using a blood gas analyzer. 
Based on lung function and blood gases, patients were strati-
fied into GOLD stages for severity of COPD.14 In addition to 
determination of body weight and height, body composition 
was assessed using single-frequency bioelectrical impedance 
assessment after overnight fasting. A COPD-specific regres-
sion equation was used to calculate fat-free mass.22 Functional 
exercise capacity was assessed by the six-minute walk test 
(performed twice23) and was expressed as percentage of 
predicted.24 Self-perceived dyspnea in relation to physical 
disability was measured by the Medical Research Council 
(MRC) dyspnea scale.25 The St George’s Respiratory Ques-
tionnaire (SGRQ) was used to assess disease-specific health 
status,26 consisting of three domains (symptoms, activity and 
impact) and a total score. Scores range from 0 (optimal) to 
100 points (worst).
Statistics
All statistics were performed using the Statistical Package 
for the Social Sciences (SPSS) version 17.0.0 (SPSS Inc, 
Chicago, IL). Results are expressed as the mean ± standard 
deviation. The independent samples Student’s t-test was used 
to investigate gender differences within the COPD group and 
differences between COPD patients with and without fre-
quent exacerbations. SGRQ data were stratified into quartiles. 
Differences between COPD GOLD stages, MRC strata, and 
SGRQ quartiles were investigated by one-way analysis of 
variance, using Fisher’s Least Significant Difference as a 
post hoc test. Pearson’s correlation analysis was performed 
in order to study linear relationships between the number of 
respiratory medications and parameters of integrated health 
status. Stepwise linear regression analysis was done to iden-
tify independent determinants of the prescribed number of 
respiratory drugs. Differences in the proportion of patients 
using the various categories of respiratory medications and 
individual compounds between different GOLD stages and 
between patients with and without frequent exacerbations 
were assessed using Chi-square test. All P values ,0.05 
were considered to be statistically significant.
Results
From January 1, 2005 until December 31, 2009, a total number 
of 2561 subjects was referred to CIRO+ for comprehensive 
assessment and pulmonary rehabilitation. COPD was the 
primary pulmonary diagnosis on referral by a secondary 
care respiratory physician in 1988 (78%) of these subjects. 
One-hundred and twenty nine of the subjects were excluded 
from analyses because postbronchodilator FEV1/forced vital 
capacity during assessment in CIRO+ was $0.7. The final 
analyses in this study included data from 1859 patients with 
mild to very severe COPD. Distribution of disease severity and 
other characteristics of these subjects are reported in Table 1. 
Forty-one percent of subjects were current smokers. On aver-
age, diffusion capacity was moderately impaired and subjects 
were normoxemic and normocapnic. Group values for body 
weight and fat-free mass were in the normal range. Overall, 
functional exercise capacity was moderately impaired, subjects 
experienced limitation of activity due to breathlessness during 
daily life, and had a severely impaired health status.
On average, COPD patients used 3.5 ± 1.5 respiratory 
medications. Variation in the number of respiratory drugs was 
wide (Figure 1A), with 5% of patients using no medication, 
while 22% of patients took five or more respiratory prescrip-
tions per day. The number of respiratory medications was 
comparable between male and female patients with COPD 
(3.4 ± 1.5 versus 3.5 ± 1.5, respectively, not significant). 
The number of respiratory drugs increased with advancement 
in GOLD stage (Figure 1B). Also, COPD patients in the 
Table 1 Subject characteristics (mean ± standard deviation)
Patients, number 1859 (58% males)
Age, years 64.3 ± 9.7
Current smokers 41%
FEV1, liters 1.18 ± 0.53
FEV1, % predicted 44.7 ± 18.2
FEV1/FVC 39.2 ± 11.7
COPD severity
  GOLD I, number (%) 89 (4.8)
  GOLD II, number (%) 557 (29.9)
  GOLD III, number (%) 582 (31.3)
  GOLD IV, number (%) 631 (33.9)
DLCO, % predicted 51.7 ± 18.9
BMI, kg/m2 25.2 ± 5.2
FFMI, kg/m2 16.4 ± 2.9
PaO2, kPa 9.4 ±1.3
PaCO2, kPa 5.4 ± 1.4
6MWD 416 ± 129
6MWD, % predicted 67 ± 18
MRC 3.6 ± 1.2
SGRQ, symptoms 61 ± 21
SGRQ, activity 71 ± 19
SGRQ, impact 44 ± 19
SGRQ, total 55 ± 17
Abbreviations: FEV1, forced expiratory volume in one second; FVC, forced vital 
capacity; DLCO, diffusing capacity for carbon monoxide; BMI, body mass index; FFMI, 
fat-free mass index; PaO2, arterial oxygen tension; PaCO2, arterial carbon dioxide 
tension; 6MWD, six-minute walk distance; MRC, Medical Research Council dyspnea 
score; SGRQ, St George’s Respiratory Questionnaire.
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Figure 1 Number of respiratory medications in patients with COPD (n = 1859). (A)  Variation in number of respiratory drugs in patient population. (B) Number of respiratory 
drugs in different GOLD stages. ***P , 0.001, **P , 0.01 versus GOLD 1;   ###P , 0.001 versus GOLD 2; †††P , 0.001 versus GOLD 3. (C) Number of respiratory drugs 
for quartiles of health status, indicated by SGRQ. ***P , 0.001 versus quartile 1; ###P , 0.001, ##P , 0.01 versus quartile 2; †††P , 0.001 versus quartile 3. (D) Number of 
respiratory medications in relation to Medical Research Council (MRC) dyspnea score. **P , 0.01 versus MRC 0;   ###P , 0.001, #P , 0.05 versus MRC 1;  †††P , 0.001 versus 
MRC 2;   $$$P , 0.001 versus MRC 3;  XXP , 0.01 versus MRC 4. 
Abbreviations: COPD, chronic obstructive pulmonary disease; GOLD, Global Initiative for Chronic Obstructive Lung Disease; MRC, Medical Research Council; SGRQ, 
St George’s Respiratory Questionnaire.
upper quartiles of total SGRQ score and those with highest 
(worst) MRC dyspnea grade used more respiratory drugs, 
compared with those having lower scores on these outcomes 
(Figure 1C and D).
In bivariate correlation analysis, FEV1 (% predicted, 
r = −0.346, P , 0.001), DLCO (r = −0.097, P , 0.001), number 
of exacerbations in previous 12 months (r = 0.314, P , 0.001), 
six-minute walk test (r = −0.300, P , 0.001), arterial oxygen 
tension (−0.050, P , 0.05), arterial carbon dioxide ten-
sion (r = 0.058, P , 0.05), MRC dyspnea grade (r = 0.339, 
P , 0.001), SGRQ symptom score (r = 0.299, P , 0.001), 
SGRQ activity score (r = 0.325, P , 0.001), SGRQ impact 
score (r = 0.301, P , 0.001), and SGRQ total score (r = 0.345, 
P , 0.001) all significantly correlated with the number of 
respiratory drugs of the patients, while correlations with age 
(r = 0.024), body mass index (r = 0.043) and fat-free mass index 
(r = 0.031) were absent. Since there were multiple bivariate 
correlations between these factors, significant parameters were 
entered in a stepwise regression model with the number of 
respiratory medications as the dependent variable (Table 2). 
In addition to FEV1 (% predicted), SGRQ total score, number 
of exacerbations in the previous 12 months, six-minute walk 
test, arterial oxygen tension, arterial carbon dioxide tension, 
and DLCO individually contributed to the model, while MRC 
dyspnea grade was excluded. The proportion of variance 
explained by the model (R2) was 0.22.
The percentage of COPD patients using the various 
  categories of respiratory medications for the total group 
and for the different GOLD stages is displayed in Table 3. 
In general, the three most commonly used respiratory drugs 
were combination products of long-acting β2-agonists/
inhaled corticosteroids, long-acting anticholinergics, and 
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Table 2 Results of stepwise regression analysis for the number of respiratory drugs in patients with COPD
Model Unstandardized coefficients Standardized coefficients t Significance
B Standard error Beta
(Constant) 6.015 0.777 7.742 0.000
SGRQ total 0.15 0.003 0.183 4.535 0.000
FEV1, % pred −0.18 0.003 −0.233 −5.484 0.000
Exacerbations, no 0.095 0.020 0.170 4.663 0.000
6MWD, meters −0.002 0.000 −0.139 −3.467 0.001
PaCO2, kPa 0.320 0.087 0.149 3.653 0.000
DLCO, % pred 0.009 0.003 0.124 3.166 0.002
PaO2, kPa −0.100 0.041 −0.097 −2.428 0.015
Abbreviations: SGRQ, St George’s Respiratory Questionnaire; FEV1, forced expiratory volume in one second; 6MWD, six-minute walk distance; PaCO2, arterial carbon 
dioxide tension; DLCO, diffusing capacity for carbon monoxide; PaO2, arterial oxygen tension.
Table 3 Percentage of patients using various categories of COPD 
medications in the total group and in the different GOLD stages 
Medication Total GOLD 1 GOLD 2 GOLD 3 GOLD 4
SABA 33.4 24.7 25.7 36.9*,### 38.2*,###
SAAC 16.3 5.6 12.9* 14.6* 22.2***,###,††
COMBI 29.0 9.0 18.3* 24.6**,# 45.3***,###,†††
LABA 23.7 16.9 19.2 25.1# 27.4*,##
LAAC 64.2 62.9 70.3 67.9 55.5###,†††
ICS 18.4 12.4 12.8 17.5# 24.9**,###,††
LABA-ICS 68.1 68.5 72.1 70.6 62.3###,†††
OCS 21.5 9.0 10.6 16.2## 37.7***,###,†††
THEO 17.8 4.5 11.1 16.2**,# 27.1***,###,†††
NAC 43.1 27.0 30.6 39.0*,## 60.1***,###,†††
Notes: Significance of differences between COPD GOLD stages is indicated by: 
***P , 0.001, **P , 0.01, *P , 0.05 versus GOLD 1; ###P , 0.001, ##P , 0.01, 
#P , 0.05 versus GOLD 2; †††P , 0.001, ††P , 0.01, †P , 0.05 versus GOLD 3.
Abbreviations: SABA, short-acting β2-agonists; SAAC, short-acting anticholinergics; 
COMBI, short-acting combination bronchodilators; LABA, long-acting β2-agonists; 
LAAC,  long-acting  anticholinergics;  ICS,  inhaled  corticosteroids;  LABA-ICS, 
combination  of  long-acting  β2-agonists  and  inhaled  corticosteroids;  OCS,  oral 
corticosteroids; THEO, oral theophylline; NAC, oral N-acetylcysteine. 
N-  acetylcysteine. The use of short-acting bronchodilators 
significantly increased with each advance in GOLD stage 
(Figure 2), and this increase in use in parallel with dis-
ease severity was observed for all individual components 
(Table 3). The percentage of patients using long-acting 
bronchodilators (either as a single inhaler or as part of a 
combination inhaler) was comparable in all GOLD stages, 
except for significantly less frequent use in GOLD 4 com-
pared with GOLD 3 patients (Figure 2), as a result of a lower 
percentage of patients using long-acting anticholinergics in 
very severe COPD (Table 3). On average, almost 90% of 
GOLD 1 patients were taking any prescription containing a 
long-acting bronchodilator.
While patients with mild COPD used significantly 
fewer inhaled corticosteroids than patients with severe 
or very severe disease, the proportion of patients using 
inhaled corticosteroids (either as a single inhaler or as part 
of a combination inhaler) was comparable in GOLD 2, GOLD 
3, and GOLD 4   (Figure 2). As shown in Figure 2, 78% of 
GOLD 1 patients and 84% of GOLD 2 patients used any 
prescription of inhaled corticosteroids. There was a gradual 
increase in the proportion of patients using oral corticoster-
oids, theophylline, and N-acetylcysteine from mild to very 
severe disease (Table 3), with GOLD 3 and GOLD 4 patients 
using these oral drugs significantly more frequently.
COPD patients with frequent exacerbations were char-
acterized by younger age, more severe airflow obstruction, 
increased MRC dyspnea grade, elevated scores on all SGRQ 
domains, and impaired six-minute walk test compared with 
patients with less frequent exacerbations (Table 4). A higher 
proportion of patients with frequent exacerbations used any 
inhaled corticosteroid in comparison with patients without 
frequent exacerbations (89.4% versus 83.7%, P , 0.01), 
which was explained by a higher percentage of patients 
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Figure 2 Proportion of COPD patients using various classes of inhaled respiratory 
medications,  after  stratification  for  GOLD  stage.  Black  bars,  short-acting 
bronchodilators; light gray bars, long-acting bronchodilators; dark gray bars, inhaled 
corticosteroids. 
Notes: Significance of differences between GOLD COPD stages is indicated by: 
***P , 0.001, *P , 0.05 versus GOLD 1; ###P , 0.001 versus GOLD 2; †††P , 0.001, 
†P , 0.05 versus GOLD 3. 
Abbreviations: COPD, chronic obstructive pulmonary disease; GOLD, Global 
Initiative for Chronic Obstructive Lung Disease.
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Table 4 Differences in clinical characteristics between COPD 
patients with frequent exacerbations ($3 in the last year) and 
patients  without  frequent  exacerbations  (mean  ±  standard 
deviation)
Variables Frequent 
exacerbations
No frequent 
exacerbations
Age, years 63.1 ± 9.4 64.8 ± 9.7**
FEV1, liters 1.05 ± 0.48 1.23 ± 0.52***
FEV1, % predicted 40.7 ± 17.2 46.2 ± 18.1***
FEV1/FVC 38.4 ± 11.7 39.5 ± 11.6
DLCO, % predicted 50.1 ± 20.1 52.3 ± 18.6
BMI, kg/m2 25.2 ± 2.0 25.1 ± 5.2
FFMI, kg/m2 16.2 ± 2.3 16.4 ± 2.3*
PaO2, kPa 9.4 ± 3.9 9.5 ± 3.2
PaCO2, kPa 5.4 ± 0.7 5.4 ± 1.9
6MWD 390 ± 127 432 ± 127***
6MWD, % predicted 63 ± 17 69 ± 17***
MRC 3.9 ± 1.1 3.4 ± 1.2***
SGRQ, symptoms 68 ± 18 57 ± 21***
SGRQ, activity 78 ± 16 70 ± 20***
SGRQ, impact 50 ± 17 42 ± 19***
SGRQ, total 61 ± 15 53 ± 17***
Notes:  Significance  of  differences  between  groups  indicated  by:  ***P  ,  0.001; 
**P , 0.01; *P , 0.05.
Abbreviations: FEV1, forced expiratory volume in one second; FVC, forced vital 
capacity; DLCO, diffusing capacity for carbon monoxide; BMI, body mass index; FFMI, 
fat-free mass index; PaO2, arterial oxygen tension; PaCO2, arterial carbon dioxide 
tension; 6MWD, six-minute walk distance; MRC, Medical Research Council dyspnea 
score; SGRQ, St George’s Respiratory Questionnaire.
using single-inhaler corticosteroids (24.1% versus 14.7%, 
P , 0.001) while the proportion of patients taking corticos-
teroids as part of a combination product was comparable 
(66.7% versus 69.5%) in both groups. The use of oral corti-
costeroids (33.5% versus 14.1%, P , 0.001), theophylline 
(24.6% versus 14.3%, P , 0.001), N-acetylcysteine (53.9% 
versus 36.9%, P , 0.001), and short-acting bronchodilators 
(78.1% versus 60.7%, P , 0.001) was significantly more 
prevalent in patients with frequent exacerbations compared 
with patients with no or less frequent exacerbations. The 
proportion of patients using long-acting bronchodilators was 
comparable between both groups, although long-acting anti-
cholinergics were less frequently used in those with frequent 
exacerbations, compared to patients with no or less frequent 
exacerbations (60.7% versus 66.3%, P , 0.001).
Discussion
This study shows that polypharmacy with respiratory drugs is 
common in patients with mild to very severe COPD referred 
for pulmonary rehabilitation. In addition to the severity of 
chronic airflow limitation, health status and the number of 
recent exacerbations are independent predictors of number 
of respiratory medications used by these patients. A vast 
  majority of patients use long-acting bronchodilators and 
inhaled corticosteroids and the proportion of COPD patients 
taking these respiratory medications is comparable in all 
stages of the disease. Also, the use of inhaled or systemic 
corticosteroids is not restricted to patients with frequent 
exacerbations. The results of this study suggest that actual 
drug use in COPD patients is inconsistent with the current 
GOLD guidelines and that overprescription of long-acting 
bronchodilators and both inhaled and systemic corticos-
teroids is very common in COPD patients with persistent 
symptoms. Overprescription of respiratory drugs is not only 
a potential source of unnecessary expense, but is also a risk 
factor for adverse drug effects and poor adherence.
The overall approach to management of stable COPD 
is characterized by an increase in pharmacologic treatment 
depending on both severity of airflow obstruction and the 
clinical status of the patient. The observed association 
between number of respiratory drugs used by patients with 
COPD and GOLD stage is in line with the recommended 
cumulative introduction of pharmacotherapy. Regarding 
this approach, the positive association between the number 
of recent exacerbations and the number of medications 
could also be anticipated. However, health status was an 
additional independent predictor of polypharmacy in this 
study. One possible explanation for this finding is that new 
pharmaceutical agents are repeatedly added during visits 
to the outpatient clinic in COPD patients with persistent 
symptoms and/or limited physical activity. This hypothesis 
is supported by the fact that poor walking distance was an 
independent predictor of the number respiratory drugs in 
this study. By the time that the complete pharmacologic 
arsenal has been applied and patients nevertheless remain 
symptomatic, they are referred for pulmonary rehabilita-
tion by the respiratory physicians.27 The use of multiple 
respiratory medications in this study may thus reflect the 
tertiary care setting of this study, including more complex 
COPD patients, irrespective of GOLD stage. Nevertheless, 
pulmonary drug therapy remains inconsistent with the cur-
rent GOLD guidelines. Furthermore, it should be noted that 
not more than 22% of variance in the number of respira-
tory medications was explained by the presented model. 
Despite the inclusion of a comprehensive set of objective 
parameters in the current analysis, other factors probably 
contribute. The duration of disease, number of consulted 
physicians, and presence of comorbid conditions are some 
of these potential contributing factors.
Preserving health status is one of the main objectives 
of treatment for COPD, and pharmaceutical trials have 
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  consistently shown positive effects on this outcome.5,6 
However, in the present study, the worst health status was 
observed in those patients using the most respiratory drugs, 
independent of the severity of disease. Although health status 
in these patients might have been even more impaired with 
less comprehensive pharmacotherapy, this observation sug-
gests that the effects of respiratory drugs on health status are 
limited and emphasizes the importance of nonpharmacologic 
interventions in COPD patients with persistent symptoms, 
like pulmonary rehabilitation.27
Although polypharmacy with respiratory drugs is likely 
an indicator of poor health status in COPD, a direct nega-
tive effect of multiple medication on health status cannot 
be excluded. Use of multiple medication is associated with 
poor self-rated health status among all age groups in the 
general population.28 In line with the present study, high daily 
consumption of respiratory drugs was the only independent 
correlate of all component scores and of the total SGRQ 
score in a cross-sectional study including elderly patients 
with asthma and COPD.29
Bronchodilator medications for inhaled therapy are 
central to the symptomatic management in COPD, and 
improve lung function, exercise performance, and health 
status.14 Short-acting bronchodilators are recommended for 
all stages of disease when needed. Contrary to expectations, 
the majority of GOLD 1 patients and 15%–50% of GOLD 
2 to 4 patients did not use any short-acting bronchodilators, 
despite being referred for pulmonary rehabilitation due to 
persistent symptoms. This suggests undertreatment with this 
class of respiratory drugs and inconsistency with the current 
GOLD guideline.14 On the other hand, the present study found 
a marked predominance of use of long-acting bronchodila-
tors in both mild and more advanced disease. This suggests 
that long-acting bronchodilators are prescribed as first-line 
therapy in all symptomatic patients with COPD, irrespective 
of GOLD stage. Although the international guidelines advise 
the use of long-acting bronchodilators only in GOLD stages 
2 to 4,14 several pharmaceutical trials indicated additional 
beneficial effects of long-acting bronchodilators over short-
acting bronchodilators on lung function, dyspnea, and health 
status in patients with severe COPD.30,31 Little is known 
about the effects of long-acting bronchodilators in mild-to-
moderate COPD. A recent prespecified subgroup analysis of 
the Understanding Potential Long-Term Impacts on Func-
tion with Tiotropium (UPLIFT) study showed improved 
outcomes, including lung function and health status, with a 
long-acting anticholinergic drug compared with placebo.13 
In addition, long-term long-acting anticholinergic therapy 
seemed to reduce the rate of decline in postbronchodilator 
FEV1 in moderate COPD,13 suggesting that starting therapy 
with long-acting anticholinergics is indicated at a more early 
stage of the disease.
According to the present GOLD guideline, the role of 
regular treatment with inhaled corticosteroids in the manage-
ment of COPD is limited to symptomatic patients with severe 
to very severe disease (FEV1 , 50% predicted) and repeated 
exacerbations.14 In this category of patients, treatment with 
inhaled corticosteroids reduces the frequency of exacerbations 
and improves health status.32 In the present analyses of actual 
drug use in clinical practice, the majority of patients with 
COPD used inhaled corticosteroids, irrespective of the degree 
of airflow limitation and occurrence of exacerbations. This 
observation is in line with an earlier study reporting a very 
high proportion of COPD patients being administered inhaled 
corticosteroids, conflicting with national guidelines at that 
time.33 Although there still is no clear evidence of the benefit 
of earlier treatment with inhaled corticosteroids in COPD, a 
recent randomized placebo-controlled trial in GOLD stage 2 
patients showed that long-term inhaled corticosteroid therapy 
improved airway inflammation, dyspnea and health status.12 
Furthermore, in contrast with older large COPD trials,34,35 
this trial suggested that inhaled corticosteroid therapy has the 
potential to attenuate FEV1 decline in moderate disease.
Short-term courses with systemic corticosteroids are 
advised in the management of COPD exacerbations but, 
based on lack of evidence of benefit, chronic treatment 
should be avoided.14 Contrary to the GOLD recommenda-
tions, a substantial proportion of patients in the current 
study were taking long-term oral prednisone, especially 
in the subgroup of patients with frequent exacerbations. 
In view of the well known toxicity of these drugs, this is 
an unfavorable observation. Although the current GOLD 
guideline does not advocate the use of antioxidants, such as 
N-acetylcysteine, in the treatment of stable COPD,14 wide-
spread use of this agent in all GOLD stages was reported 
in the current real-life analyses. Although adverse effects 
of N-acetylcysteine are limited,36 overprescription usually 
increases the costs of treatment, which is an unwanted 
consequence considering the high impact of COPD on the 
health care system.1 Finally, a significant proportion of 
patients in this study used oral theophylline, which is con-
sidered an effective bronchodilator in COPD, subordinated 
to inhaled bronchodilator therapy due to the potential for 
toxicity.14 However, recent studies suggest a future role for 
combination therapy of low-dose theophylline with inhaled 
corticosteroids in COPD.37
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The results of the present survey confirm the clinical 
observations of respiratory prescriptions during day-to-day 
contact with COPD patients. They indicate that the routine 
practice of respiratory physicians is only partially consis-
tent with current guidelines. There are several potential 
causes for the discrepancy between observed respiratory 
medication use and international guidelines. Following 
worldwide dissemination of the GOLD guidelines since 
their introduction nearly a decade ago, it is unlikely that 
respiratory physicians are not aware of these international 
recommendations. However, traditional ongoing medical 
education in the form of printed copies of guidelines or 
lectures may not be effective in implementation of new or 
updated guidelines and altering physician performance.38 
Another reason for nonadherence to the guidelines could be 
an insufficient clinical response to initial pharmacotherapy 
in patients with COPD, reflected by persistence of symp-
toms, reduced exercise capacity, or poor health status. Being 
confronted with a symptomatic and disabled COPD patient 
could persuade a respiratory physician to initiate additional 
or alternative medication inconsistent with the guidelines. 
In addition, disagreement with the suggested approach and 
knowledge of data not yet incorporated into the current 
directives are possible reasons for not adhering to guide-
lines. New insights in the effects of early treatment with 
long-acting bronchodilators,13 inhaled corticosteroids,12 or 
theophylline37 are some examples of the recent develop-
ments in the field of pharmacologic management of COPD, 
that require subsequent analyses before being integrated in 
future international guidelines.
In summary, this study reported discrepancies between 
international guidelines for pharmacologic management of 
COPD and actual prescription rates in patients with mild to 
very severe COPD referred for pulmonary rehabilitation. 
These symptomatic patients use multiple respiratory medica-
tions, and actual respiratory drug use is largely independent 
of the severity of chronic airflow limitation and the rate of 
exacerbations. However, health status is an independent 
predictor of polypharmacy in these patients. In consideration 
of the existing GOLD guideline, long-acting bronchodila-
tors and both inhaled as well as systemic corticosteroids for 
maintenance therapy are overprescribed in patients with mild 
to moderate COPD. In view of the already vast economic 
impact of COPD on the health care system, overprescrip-
tion and polypharmacy should be avoided, and respiratory 
physicians should be encouraged to adhere to evidence-based 
guidelines for COPD management until new pharmacologic 
strategies are established.
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